Veru (NASDAQ:VERU) and Sophiris Bio (OTCMKTS:SPHS) Financial Comparison

Veru (NASDAQ:VERU) and Sophiris Bio (OTCMKTS:SPHS) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, dividends, risk and profitability.

Risk & Volatility

Veru has a beta of -0.23, meaning that its stock price is 123% less volatile than the S&P 500. Comparatively, Sophiris Bio has a beta of 1.94, meaning that its stock price is 94% more volatile than the S&P 500.

Analyst Ratings

This is a summary of current ratings and price targets for Veru and Sophiris Bio, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Veru	0	1	1	0	2.50
Sophiris Bio	0	0	0	0	N/A

Veru currently has a consensus target price of $2.00, suggesting a potential upside of 257.14%.

Profitability

This table compares Veru and Sophiris Bio’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Veru	-571.20%	-374.04%	-136.93%
Sophiris Bio	N/A	N/A	N/A

Earnings and Valuation

This table compares Veru and Sophiris Bio’s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Veru	$16.30 million	4.73	-$93.09 million	($1.13)	-0.50
Sophiris Bio	N/A	N/A	N/A	N/A	N/A

Sophiris Bio has lower revenue, but higher earnings than Veru.

Institutional and Insider Ownership

23.1% of Veru shares are owned by institutional investors. 14.2% of Veru shares are owned by insiders. Comparatively, 4.5% of Sophiris Bio shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

About Veru

Veru Inc., a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections. The company's development program includes enobosarm, a selective androgen receptor modulator for treatment of augment fat loss and to prevent muscle loss in sarcopenic obese and overweight elderly patients; Enobosarm, a selective androgen receptor modulator for the treatment of AR+ ER+ HER2- metastatic breast cancer; and sabizabulin, a microtubule disruptor for the treatment of hospitalized patients with viral lung infection on oxygen support who are at high risk for viral induced ARDS and death. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. was incorporated in 1971 and is headquartered in Miami, Florida.

About Sophiris Bio

Sophiris Bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of products for the treatment of urological diseases. The company was founded by James L. Heppell in May 2003 and is headquartered in La Jolla, CA.